Welcome to our dedicated page for Relmada Therapeutics news (Ticker: RLMD), a resource for investors and traders seeking the latest updates and insights on Relmada Therapeutics stock.
Relmada Therapeutics, Inc. (Nasdaq: RLMD) is a clinical-stage biotechnology company whose news flow centers on the development of NDV-01 for non-muscle invasive bladder cancer (NMIBC) and sepranolone for central nervous system conditions. Company press releases frequently highlight clinical data readouts, regulatory interactions, and financing events that shape the outlook for its pipeline.
Recent news has focused on NDV-01, a sustained-release, intravesical formulation of gemcitabine and docetaxel in development for NMIBC. Relmada has reported 6‑month and 9‑month follow-up data from an open-label Phase 2 study, including complete response rates at various time points, safety findings, and outcomes such as absence of progression to muscle-invasive disease and lack of radical cystectomy among reported patients. Updates also describe treatment-related adverse events and their severity profile.
Another key theme in RLMD news is FDA regulatory feedback. The company has announced written guidance from the FDA supporting two potential registrational study paths for NDV-01: a single-arm trial in high-grade, 2nd-line BCG-unresponsive NMIBC with carcinoma in situ and a randomized-to-observation trial in intermediate-risk NMIBC in the adjuvant setting. These items are often accompanied by timelines for anticipated Phase 3 trial initiation and expectations around a 505(b)(2) regulatory pathway.
Relmada’s news feed also covers corporate and financial updates, including quarterly financial results, underwritten equity offerings, Nasdaq listing compliance notices, and additions to its clinical advisory board. For sepranolone, press releases describe its GABAA-modulating mechanism and planned Phase 2 development in Prader-Willi syndrome and other compulsivity-related disorders. Investors monitoring RLMD news can use this page to follow clinical milestones, regulatory developments, capital-raising activities, and other disclosures that the company furnishes through GlobeNewswire and SEC-related announcements.
Relmada Therapeutics (NASDAQ:RLMD), a clinical-stage biotechnology company focused on oncology and central nervous system therapies, will host a conference call and webcast on Thursday, August 7, 2025, at 4:30 PM ET to discuss Q2 2025 financial results and business updates.
The conference call will be accessible via US dial-in (1-877-407-0792) and International dial-in (1-201-689-8263) with conference code 13754263. A webcast replay will be available in the Investors section of Relmada's website.
Relmada Therapeutics (NASDAQ:RLMD) has appointed renowned urologic oncologist Dr. Yair Lotan as Chair of its Clinical Advisory Board (CAB). Dr. Lotan, with over 20 years of experience in bladder cancer care and clinical development, will support the advancement of NDV-01, the company's treatment for non-muscle invasive bladder cancer (NMIBC).
The appointment comes as Relmada prepares to initiate a Phase 3 trial for NDV-01 in H1 2026, following positive Phase 2 data presented at AUA 2025. NDV-01's ready-to-use sustained release formulation aims to improve upon the current gemcitabine/docetaxel combination treatment by offering easier administration outside hospital settings.
Relmada Therapeutics (NASDAQ: RLMD), a clinical-stage biotechnology company, has scheduled its first quarter 2025 financial results conference call and webcast for Monday, May 12, 2025, at 4:30 PM ET. The event will cover financial performance for Q1 ending March 31, 2025, and provide updates on recent business developments.
Investors can access the conference via US dial-in (1-877-407-0792) or International dial-in (1-201-689-8263) using conference code 13753596. A webcast replay will be available in the Investors section of Relmada's website.
Relmada Therapeutics announced positive initial Phase 2 data for NDV-01, their treatment for non-muscle invasive bladder cancer (NMIBC), at AUA2025. The study showed remarkable efficacy with 90% of patients achieving high-grade disease-free status.
Key results include:
- 85% overall response rate at 3 months (17/20 patients)
- 83.3% high-grade recurrence-free survival in papillary disease
- 100% complete response in CIS patients
- 100% disease-free status at 6 months for evaluable patients
The treatment showed strong effectiveness across all patient groups, including both BCG-naïve and BCG-unresponsive patients. NDV-01's safety profile was favorable, with only mild, temporary side effects reported. The treatment can be administered in under 10 minutes, potentially offering a significant advancement in outpatient bladder cancer care.
The ongoing study has enrolled 26 patients total, with 20 reaching the 3-month assessment mark. The company aims to position NDV-01 as a leading therapy for NMIBC treatment.
Relmada Therapeutics (NASDAQ: RLMD) has announced its upcoming presentation at the American Urology Association (AUA2025) conference in Las Vegas, scheduled for April 26-29th, 2025. The company will present data on NDV-01, their investigational treatment, during the Clinical Trials in Progress Session.
The abstract, focusing on a prospective open-label study, will evaluate the safety and efficacy of intravesical sustained release Gemcitabine Docetaxel combination (NDV-01) in High Risk NMIBC. The presentation is scheduled for April 28, 2025, from 10:04 AM PT to 10:12 AM PT in Hall C, The Square, Learning Lab.
Relmada Therapeutics (Nasdaq: RLMD) has announced its upcoming presentation at the American Urology Association (AUA2025) conference in Las Vegas, scheduled for April 26-29th, 2025. The company will present data on NDV-01, a combination therapy of intravesical sustained release Gemcitabine and Docetaxel.
The presentation, categorized as Paradigm-Shifting, will focus on a prospective open-label study evaluating NDV-01's safety and efficacy in High Risk NMIBC. The abstract presentation is scheduled for April 28, 2025, at 10:04 AM PT.
Relmada Therapeutics (NASDAQ: RLMD) has announced its upcoming presentation at the American Urology Association (AUA2025) conference in Las Vegas, scheduled for April 26-29, 2025. The company will present data on NDV-01, a combination therapy of intravesical sustained release Gemcitabine and Docetaxel.
The presentation, categorized as Paradigm-Shifting, will focus on a prospective open-label study evaluating the safety and efficacy of NDV-01 in High Risk NMIBC. The abstract will be presented on Monday, April 28, 2025, at 10:04 AM PT.
Relmada Therapeutics (RLMD) reported Q4 and full-year 2024 results, highlighting progress in two Phase 2 programs. The company expects topline Phase 2 data for NDV-01, treating high-grade non-muscle invasive bladder cancer, at AUA 2025 in April. They're also advancing sepranolone, a neurosteroid, towards Phase 2b studies in Tourette syndrome and Prader-Willi Syndrome.
Financial highlights include: Cash position of $44.8 million as of December 31, 2024; Q4 net loss of $18.6 million ($0.62 per share), improved from $25.1 million ($0.84 per share) in Q4 2023; Full-year 2024 net loss of $80 million ($2.65 per share), compared to $98.8 million in 2023. R&D expenses decreased to $46.2 million from $54.8 million in 2023.
The company expects to initiate registration-track studies for both NDV-01 and sepranolone between late Q4 2025 and early 2026, with current cash runway extending into H1 2026.
FAQ
What is the current stock price of Relmada Therapeutics (RLMD)?
What is the market cap of Relmada Therapeutics (RLMD)?
